These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 32213045)

  • 1. Local health departments and the implementation of evidence-based policies to address opioid overdose mortality.
    Feuerstein-Simon R; Lowenstein M; Sharma M; Dupuis R; Luna Marti X; Cannuscio CC
    Subst Abus; 2020; 41(4):468-474. PubMed ID: 32213045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States.
    Lambdin BH; Davis CS; Wheeler E; Tueller S; Kral AH
    Drug Alcohol Depend; 2018 Jul; 188():370-376. PubMed ID: 29776688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling up overdose education and naloxone distribution in Kentucky: adoption and reach achieved through a "hub with many spokes" model.
    Knudsen HK; Freeman PR; Oyler DR; Oser CB; Walsh SL
    Addict Sci Clin Pract; 2023 Nov; 18(1):72. PubMed ID: 38031180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.
    Zang X; Macmadu A; Krieger MS; Behrends CN; Green TC; Morgan JR; Murphy SM; Nolen S; Walley AY; Schackman BR; Marshall BD
    Int J Drug Policy; 2021 Dec; 98():103435. PubMed ID: 34482264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of opioid overdose education and naloxone distribution in New York City.
    Behrends CN; Gutkind S; Winkelstein E; Wright M; Dolatshahi J; Welch A; Paone D; Kunins HV; Schackman BR
    Subst Abus; 2022; 43(1):692-698. PubMed ID: 34666633
    [No Abstract]   [Full Text] [Related]  

  • 6. Organize and mobilize for implementation effectiveness to improve overdose education and naloxone distribution from syringe services programs: a randomized controlled trial.
    Lambdin BH; Bluthenthal RN; Garner BR; Wenger LD; Browne EN; Morris T; Ongais L; Megerian CE; Kral AH
    Implement Sci; 2024 Feb; 19(1):22. PubMed ID: 38419058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-led approaches to making naloxone available in public settings: Implementation experiences in the HEALing communities study.
    Starbird LE; Onuoha E; Corry G; Hotchkiss J; Benjamin SN; Hunt T; Schackman BR; El-Bassel N
    Int J Drug Policy; 2024 Jun; 128():104462. PubMed ID: 38795466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community-based opioid overdose prevention programs providing naloxone - United States, 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Feb; 61(6):101-5. PubMed ID: 22337174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statewide Availability of Buprenorphine/Naloxone in Acute Care Hospitals.
    Pham S; Haigh A; Barrett E
    J Addict Med; 2022 Jan-Feb 01; 16(1):e48-e51. PubMed ID: 33758118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A medical student-led model for telephone-based opioid overdose education and naloxone distribution during the COVID-19 pandemic.
    Hughes TM; Kalicki A; Huxley-Reicher Z; Toribio W; Samuels DL; Weiss JJ; Herscher M; Wang L
    Subst Abus; 2022; 43(1):988-992. PubMed ID: 35435812
    [No Abstract]   [Full Text] [Related]  

  • 13. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid overdose education and naloxone distribution: Development of the Veterans Health Administration's national program.
    Oliva EM; Christopher MLD; Wells D; Bounthavong M; Harvey M; Himstreet J; Emmendorfer T; Valentino M; Franchi M; Goodman F; Trafton JA;
    J Am Pharm Assoc (2003); 2017; 57(2S):S168-S179.e4. PubMed ID: 28292502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of a naloxone distribution plan in a veteran population who experienced an opioid-related overdose event.
    Alexander M; Hooker J; Stratton M; Huh M; Houck K
    J Am Pharm Assoc (2003); 2024; 64(3):101999. PubMed ID: 38151200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overdose, Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Intern Med; 2024 Aug; 184(8):954-962. PubMed ID: 38884975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study.
    Winhusen T; Walley A; Fanucchi LC; Hunt T; Lyons M; Lofwall M; Brown JL; Freeman PR; Nunes E; Beers D; Saitz R; Stambaugh L; Oga EA; Herron N; Baker T; Cook CD; Roberts MF; Alford DP; Starrels JL; Chandler RK
    Drug Alcohol Depend; 2020 Dec; 217():108325. PubMed ID: 33091842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations for the design of overdose education and naloxone distribution interventions: results of a multi-stakeholder workshop.
    Sellen K; Markowitz B; Parsons JA; Leece P; Handford C; Goso N; Hopkins S; Klaiman M; Shahin R; Milos G; Wright A; Charles M; Morrison L; Strike C; Orkin A;
    BMC Public Health; 2023 May; 23(1):888. PubMed ID: 37189052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014.
    Wheeler E; Jones TS; Gilbert MK; Davidson PJ;
    MMWR Morb Mortal Wkly Rep; 2015 Jun; 64(23):631-5. PubMed ID: 26086633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (Helping End Addiction Long-Term®) communities study.
    Knudsen HK; Walker DM; Mack N; Kinnard EN; Huerta TR; Glasgow L; Gilbert L; Garner BR; Dasgupta A; Chandler R; Walsh SL; Tin Y; Tan S; Sprunger J; Sprague-Martinez L; Salsberry P; Saucier M; Rudorf M; Rodriguez S; Oser CB; Oga E; Nakayima J; Linas BS; Lefebvre RC; Kosakowski S; Katz RE; Hunt T; Holman A; Holloway J; Goddard-Eckrich D; Fareed N; Christopher M; Aldrich A; Adams JW; Drainoni ML
    Prev Med; 2024 Aug; 185():108034. PubMed ID: 38857770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.